A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

NCT05744921 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG: Pozelimab
DRUG: Cemdisiran

Sponsor

Regeneron Pharmaceuticals